IDENIX is a biopharmaceutical company focused on the treatment of hepatitis C virus (HCV) infections.
The “X” became an iconic graphic design element throughout the company’s identity system, conveying the targeted nature of the company’s drug delivery capabilities.
A few short months following the launch of the new brand, Merck & Co. acquired IDENIX for $3.85 billion.